(P-2041) In Vitro Resistance Profiling of S-892216, a Second Generation SARS-CoV-2 3CL^pro Inhibitor for the Treatment of COVID-19

Saturday, October 19, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Sho Kawashima (he/him/his)

Resercher
Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan

Haruaki Nobori, PhD (he/him/his)

Manager
SHIONOGI & CO., LTD.
Toyonaka-shi, Osaka, Japan
MO

Miyako Okane, n/a

Shionogi TechnoAdvance Research CO., Ltd.
Toyonaka, Osaka, Japan
TH

Takashi Hashimoto, n/a

Shionogi TechnoAdvance Research Co., Ltd.
Toyonaka, Osaka, Japan
KI

Kae Inoue, n/a

Shionogi TechnoAdvance Research Co., Ltd.
Toyonaka, Osaka, Japan
YY

Yuko Yamano, n/a

Shionogi TechnoAdvance Research CO., Ltd.
Toyonaka, Osaka, Japan
KF

Keiko Funabiki, n/a

Shionogi TechnoAdvance Research CO., Ltd.
Toyonaka, Osaka, Japan
MW

Michie Watanabe, n/a

Shionogi TechnoAdvance Research CO., Ltd.
Toyonaka, Osaka, Japan
KB

Kaoru Baba, n/a

Shionogi TechnoAdvance Research, Co., Ltd.
Toyonaka, Osaka, Japan
Keita Fukao, MD (he/him/his)

Director Head of Infectious Diseases 3
Shionogi&Co., Ltd.
Toyonaka, Osaka, Japan
TK

Teruhisa Kato, PhD

Shionogi & Co., Ltd.
Toyonaka, Osaka, Japan